腺苷钴胺辅助治疗三叉神经痛60例

Clinical Efficacy and Safety of Adding Adenosine Cobaltamine on Trigeminal Neuralgia in 60 Cases

目的观察腺苷钴胺治疗三叉神经痛的临床疗效及安全性。方法将2012年1月至2015年1月收治的原发性三叉神经痛患者120例随机分为两组,各60例。对照组给予卡马西平常规治疗,观察组在此基础上加用腺苷钴胺肌肉注射,均治疗4周。结果观察组总有效率为95.00%,明显高于对照组的81.67%(P<0.05);与治疗前比较,治疗后1,2,4周两组患者疼痛对生活质量影响评分均降低(P<0.05),治疗后4周观察组降低更显著(P<0.05);两组患者头痛、呕吐、眩晕及视物模糊等不良反应发生率无统计学差异(P>0.05);随访半年,观察组复发3例(5.00%),对照组复发11例(18.33%),观察组复发率显著低于对照组(P<0.05)。结论在常规治疗基础上加用腺苷钴胺治疗原发性三叉神经痛,临床疗效明确,能有效缓解疼痛,提高患者生活质量,安全性好,复发率更低。

Objective To observe the clinical curative effect and safety of adenosine cobaltamine in treating of trigeminal neuralgia. Methods 120 Patients of Primary trigeminal neuralgia in the hosPital between January 2012 and January 2015 were randomly divided into the observation grouP and the control grouP,60 cases in each grouP. The control grouP were given carbamazePine treatment,and the observation grouP were combined with adenosine cobaltamine injections based on the above treatment, for 4 weeks. Results The total effective rate of the observation grouP was 95. 00%, which was higher than 81. 67% of the control grouP （ P 〈 0. 05 ）;comPared with before treatment, the Pain on quality of life scores of two grouPs after treatment were both decreased （ P 〈 0. 05 ）;4 weeks after treat-ment, the influence of Pain on the quality of life in the observation grouP was significantly lower than the control grouP （ P 〈 0. 05 ）;the incidence of adverse reactions in the two grouPs had no statistical difference （ P 〉 0. 05 ）;in the follow-uP after 6 months, the re-currence in the observation grouP were 3 Patients （ 5. 00%） which is significanfly lower than 11 Patients （ 18. 33%） in the control grouP （ P 〈 0. 05 ） . Conclusion Adding adenosine cobaltamine on the conventional treatment in Patients with Primary trigeminal neuralgia treated has clear clinical curative effect, can effectively relieve Pain, imProve the Patient＆#39;s quality of life with good safety and low reoc-curence rate, and is worth of clinical Promotion.